The National Institute for Health and Care Excellence (NICE) has recommended Janssen's Tremfya as a cost-effective treatment for plaque psoriasis, Pharma Times reported on Friday.
A Final Appraisal Determination was published by the cost regulator to back the funding for the drug, which was launched in the UK in the November.
Tremfya (guselkumab) is the first biologic to selectively target interleukin (IL)-23, a key protein involved in the immune inflammatory response in psoriasis.
The Final Appraisal Determination was fast-tracked as a result of the European approval in November last year. Approval was based on Phase III trials, VOYAGE 1 and VOYAGE 2, which showed high rates of skin clearance.
Janssen has agreed a confidential patient access scheme with the Department of Health and Social Care, offering the drug to the NHS at a reduced cost.
Boston Scientific receives FDA clearance for Asurys fluid management system
Aurinia Pharmaceuticals agrees to acquire Kezar Life Sciences
Rocket Pharmaceuticals secures FDA approval for Kresladi gene therapy in severe LAD-I
Pharming receives positive CHMP opinion for Joenja marketing authorisation
Biocytogen partner NEOK Bio secures FDA IND clearance for cancer therapy candidate
Eisai and Nuvation Bio report taletrectinib MAA validated by European regulator
Novo Nordisk's Awiqli once-weekly basal insulin treatment approved by US FDA
Lupin reports tentative FDA approval for Pitolisant Tablets
Clarity Pharmaceuticals signs copper-64 manufacturing agreement with Theragenics
Philips launches integrated IntraSight Plus platform to enhance coronary intervention efficiency
Hope Medicine reports first patient dosed in Phase III trial of HMI-115
Orsini chosen as single-source specialty pharmacy partner for Glaukos' Epioxa
GE HealthCare's Photonova Spectra gains FDA clearance
Futura Medical reports positive home user test results for Eroxon and Intense variant